Last reviewed · How we verify
Transthyretin familial amyloid polyneuropathy
Approved treatments
- Amvuttra · Alnylam Pharmaceuticals
Amvuttra works by silencing the production of abnormal TTR protein through RNA interference. - Onpattro · Alnylam Pharmaceuticals
Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA. - Onpattro · Alnylam Pharmaceuticals
Onpattro works by silencing the production of abnormal TTR protein through RNA interference.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Transthyretin familial amyloid polyneuropathy patent landscape — cliff calendar, originator estates, attackable patents
- Transthyretin familial amyloid polyneuropathy treatment landscape brief
- Transthyretin familial amyloid polyneuropathy treatment updates RSS
Frequently asked questions about Transthyretin familial amyloid polyneuropathy
What drugs treat Transthyretin familial amyloid polyneuropathy?
Tracked treatments include Amvuttra, Onpattro.
What is the treatment for Transthyretin familial amyloid polyneuropathy?
Standard treatment for Transthyretin familial amyloid polyneuropathy includes Amvuttra, Onpattro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Transthyretin familial amyloid polyneuropathy patent cliff · Transthyretin familial amyloid polyneuropathy CI report
- Treatment: Amvuttra · Alnylam Pharmaceuticals
- Treatment: Onpattro · Alnylam Pharmaceuticals
- Treatment: Onpattro · Alnylam Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing